SEC Form 8-K Summary
Registrant: Priveterra Acquisition Corp. (the request identifies AEON Biopharma, Inc., but the filing is by Priveterra Acquisition Corp.)
Reporting date: February 25, 2022, regarding events on February 24, 2022.
Business Context and Reporting Period
This Form 8-K was filed under Item 4.02 to disclose that previously issued financial statements and the related audit report should no longer be relied upon. The affected periods include the audited balance sheet as of February 11, 2021, and interim periods ended March 31, June 30, and September 30, 2021.
Financial Metrics and Material Accounting Changes
- The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.
- The company determined that all Class A ordinary shares subject to redemption should have been classified as temporary equity rather than partially as permanent equity.
- The correction affects the presentation of Class A shares subject to redemption, additional paid-in capital, accumulated deficit, Class A ordinary shares, and earnings per share.
- The company stated that the restatement is not expected to affect its cash position or cash held in the IPO trust account.
Material Changes Versus Prior Periods
Management initially treated the accounting changes as not qualitatively material and revised the discussion in the third-quarter Form 10-Q. After further consideration, the company concluded that the changes were quantitatively material and that the affected financial statements must be restated.
The previously issued financial statements for all affected periods, together with the related audit report on the February 11, 2021 balance sheet, should no longer be relied upon. The company intends to file amendments reflecting the restatement as soon as practicable.
Guidance, Risks, and Unusual Items
- Management identified a material weakness in internal control over financial reporting during the affected periods.
- The company also concluded that its disclosure controls and procedures were not effective.
- Planned remediation includes enhanced access to accounting literature and research materials, stronger internal processes for evaluating complex accounting requirements, and increased communication with personnel and third-party accounting professionals.
- The Audit Committee discussed the matter with WithumSmith+Brown, PC, the company’s independent registered public accounting firm.
- The primary risk is delayed or incomplete restatement filings and potential reliance on financial information that has been superseded.
Key Facts for Investors to Verify
- Verify the filing entity and its relationship, if any, to AEON Biopharma, Inc.
- Review the forthcoming amendments to the February 11, 2021 balance sheet and the March 31, June 30, and September 30, 2021 Form 10-Q financial statements.
- Assess the quantitative effects of the restatement on equity classifications, accumulated deficit, and earnings per share.
- Monitor remediation of the material weakness and the effectiveness of subsequent disclosure controls.
- Confirm that cash and trust-account balances remain unaffected, as stated by management.